目的:探讨血必净注射液治疗缺氧性肺动脉高压的临床疗效.方法:将43例缺氧性肺动脉高压患者随机分为血必净注射液组(22例)和对照组(21例),两组均给予常规基础治疗,血必净注射液组加用血必净注射液,对照组加用硝苯地平,连续治疗20 d,两组治疗前后测定肺动脉平均压及体循环平均压,并行血气分析及监测血液流变学指标,评价两组治疗前后临床症状、体征积分及疗效,并观察两组不良反应发生情况.结果:治疗后两组肺动脉平均压均较治疗前明显降低(t=3.471、3.050,P<0.01),血必净注射液组肺动脉平均压较对照组下降更明显(t=2.302,P<0.05);两组治疗前后体循环平均压均无明显变化(P>0.05).两组治疗后PaO2及PaCO2均显著改善,血必净注射液组治疗后PaO2及PaCO2较对照组改善显著(P<0.05);两组血液流变学指标治疗后均较治疗前有明显改善(P<0.05).两组治疗后临床症状、体征积分较治疗前均有明显改善(t=4.582,P<0.01;t=2.137,P<0.05),血必净注射液组较对照组改善更显著(t=3.524,P<0.01),且血必净注射液组疗效明显优于对照组(X2=2.642,P<0.05).两组治疗后均未出现明显不良反应.结论:血必净注射液能有效降低缺氧性肺动脉高压患者的肺动脉平均压,改善其临床症状,并改善血液流变学指标,临床疗效较好,值得推广应用.%Objective: To evaluate the clinical efficacy of Xuebijing Injection in the treatment of hypoxic pulmonary hypertension (HPH).Methods: A total of 43 patients with HPH were randomly divided into Xuebijing Injection group (22 patients) and control group (21 patients), two groups were received routine basic treatment, and Xuebijing Injection group was additionally administered with Xuebijing Injection, control group was additionally administered with Nifedipine for 20 days, then the mean pulmonary artery pressure and systemic mean pressure before and after treatment of the two groups were determined, and blood gas analysis was done, the hemorrheology indexes were monitored, the clinical signs and symptoms points and efficacy were evaluated, and the adverse reaction of two groups were also observed.Results: The mean pulmonary artery pressure of two groups after treatment was significantly decreased than that before treatment (t=3.471, 3.050, P＜0.01), the mean pulmonary artery pressure of Xuebijing Injection group was more lower than that of control group (t= 2.302, P＜0.05); the systemic mean pressure of two groups before and after treatment had no statistical difference (P＞0.05).PaO2 and PaCO2 of two groups after treatment were significantly improved, the Xuebijing Injection group showed a better improvement than those of control group (P＜0.05); the hemorrheology indexes of two groups after treatment were significantly improved (P＜0.05).The clinical signs and symptoms points of two groups after treatment were obviously improved than those before treatment (t=4.582, P＜0.01; t=2.137, P＜0.05), and Xuebijing Injection group showed a more obvious improvement than the control group (t=3.524, P＜0.01), the efficacy of Xuebijing Injection group was obviously better than that of control group (x2=2.642, P＜0.05).No obvious adverse reaction occurred in the two groups.Conclusion: Xuebijing Injection can effectively decrease the mean pulmonary artery pressure of patients with HPH, and improve the clinical symptoms and hemorrheology indexes, it has a good clinical efficacy and deserves applied in clinic.
展开▼
